Plaintiffs Seek Relocation for Gilead Sciences Inferior HIV Drugs Trial

Plaintiffs Seek Relocation for Gilead Sciences Inferior HIV Drugs Trial

In lawsuits against pharma giant Gilead Sciences, plaintiffs across California allege they suffered ill effects from HIV drugs made and distributed by Gilead that were more harmful derivatives than other drugs the company had created but not sold until its stock of the inferior drugs was exhausted. As reported by the Daily Journal (subscription), attorneys for some of those plaintiffs are asking the judge to switch the case to a venue and location that would be more reachable and meaningful than the current Santa Clara County location. In an earlier tentative ruling, California Superior Court Judge Kenneth R. Freeman proposed that the 19 consolidated personal injury lawsuits be tried in Santa Clara County. Alternative venues suggestions include Alameda, San Francisco and Los Angeles counties. [Read more…]

National Opioid Epidemic is Creating Significant Costs for Government Bodies

San Francisco Opioid Lawsuit Filed

Well over 100 Americans die every day from prescription opioid drugs – over 36,000 American each year. These accidental drug overdoses are the leading cause of death for individuals under the age of 50 in the United States. The costs of this horrific opioid epidemic have crept up on local and larger government bodies much in the same way the addictions themselves sneak up on individuals. [Read more…]

Criminal Trial Begins for Pharmacy Exec Following Deaths Across U.S. from Contaminated Meningitis Meds

Criminal Trial Begins for Pharmacy Exec Following Deaths Across U.S. from Contaminated Meningitis Meds

As reported by USA Today, criminal prosecution of those allegedly responsible for the 2012 distribution of contaminated and lethal back pain medication begins this week as the first pharmacy executive involved goes to trial in federal court in Boston. The criminal prosecution follows a federal probe and two years of civil litigation, as hundreds were injured and at least 76 died after contracting fungal meningitis from the contaminated steroid injections. [Read more…]

Study Finds Majority of Parents Give Their Children Wrong Dose of Liquid Medication

Study Finds Majority of Parents Give Their Children Wrong Dose of Liquid Medication

A study by various pediatric clinics located in New York, Atlanta, and California has discovered that the majority of parents unknowingly provide their children with the wrong dosage of liquid medication. This is occurring in part because despite pediatric medicines including a measuring tool with related instructions, often the units on the label – milliliters, mL, teaspoon, tsp., tablespoon – differ from what’s on the tools themselves. [Read more…]

Upcoming FDA Public Hearing on Off-Label Drug and Device Use

Upcoming FDA Public Hearing on Off-Label Drug and Device Use

The U.S. Food and Drug Administration (FDA) has announced a public hearing forum to take place on November 9-10, 2016 with regard to the enforcement of rules relating to off-label drug and medical product use in the public health industry. The registration deadline to present at the hearing is October 19, 2016, and the deadline for written commentary after the hearing is January 9, 2017. [Read more…]

FDA Warning: Antipsychotic Drug Abilify Linked to Severe Compulsive Behavior and Addiction

FDA Warning: Antipsychotic Drug Abilify Linked to Severe Compulsive Behavior and Addiction

The Food and Drug Administration (FDA) has issued a formal warning that the use of the antipsychotic drug aripiprazole (Abilify, Abilify Maintena, Aristada, and also used in generic versions of the drug) has been linked to compulsive urges, which can lead to uncontrollable gambling, among other addictions. These rare but serious impulse-control problems reportedly stop when the medicine is discontinued or markedly reduced in dosage. [Read more…]

Dean Harvey Comments on FTC’s New Challenge to No-Authorized-Generic Drug Agreements

Dean Harvey Comments on FTC's New Challenge to No-Authorized-Generic Drug Agreements

The Federal Trade Commission (FTC) has made its first outright challenge towards so-called “no-authorized-generics” agreements between branded drug makers and generic drug companies. The agency initiated legal action against Endo Pharmaceuticals Inc. and other drugmakers for making anti-competitive payments through the mechanism of illegally withholding authorization for the production of generic versions of certain drugs. The FTC concludes these pharmaceutical companies violated antitrust laws by blocking lower-cost generic versions of branded drugs from consumers with pay-for-delay payments.

[Read more…]

Lexi Hazam Discusses Benicar Drug at HarrisMartin MDL Conference

Lexi Hazam Discusses Benicar Drug at HarrisMartin MDL Conference

Lieff Cabraser attorney Lexi J. Hazam is speaking at HarrisMartin’s MDL Conference: Zofran, Bard IVC and Zimmer Persona Knee Litigation on July 29, 2015 at Hotel Nikko in San Francisco. Hazam will be featured as a panelist discussing the Benicar (Olmesartan) Litigation. Hazam has been appointed by the court overseeing the nationwide Benicar MDL litigation to the Plaintiffs’ Steering Committee, and serves as Co-Chair of the MDL Plaintiffs’ Science and Experts Committee.

[Read more…]